A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads

Trial Profile

A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 May 2015

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms RALPIR
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Apr 2012 Actual end date 1 Jun 2011 added as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top